Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Immuron Ltd (NASDAQ:IMRN), an Australian pharmaceutical company, has submitted an application for the quotation of securities on the Australian Securities Exchange (ASX). The announcement was made in a report filed Wednesday with the U.S. Securities and Exchange Commission (SEC).
The company, which specializes in developing and commercializing oral immunotherapeutics for the treatment of gut-mediated diseases, included the application details in its Form 6-K submission. The filing also referenced a notice under section 708A, a provision of the Australian Corporations Act that relates to the sale of securities without a disclosure document.
The report, signed by Company Secretary Phillip Hains, was not deemed "filed" for purposes of the U.S. Securities Exchange Act of 1934, and will not be incorporated into any filings under the U.S. Securities Act of 1933 unless expressly stated.
Immuron Ltd is headquartered in Carlton, Victoria, Australia, and is classified under the pharmaceutical preparations industry. The company’s business address is Level 3, 62 Lygon Street, Carlton, Victoria, 3053. The filing is part of the company’s ongoing regulatory compliance and disclosure obligations.
This information is based on a press release statement included in the SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.